Strong credit performance and low losses
No new non-accruals in the quarter; non-accrual rate declined to 1% at fair value. Historical loss experience remains low with average annual loss rates of ~31 basis points since inception.
Adjusted NII and base dividend alignment
Adjusted net investment income (NII) was $0.31 per share in Q1 2026; the Board set the Q2 base dividend at $0.31 per share and maintained the supplemental dividend framework (50% of NII above the base).
Strong liquidity and strengthened balance sheet
Liquidity expanded to over $4 billion (cash + facility capacity) following a $400 million unsecured note offering post-quarter; net leverage reduced to 1.13x (lowest level in two years) and is within the target range of 0.90x–1.25x.
Credit rating upgrade and market validation
Moody's upgraded the company to Baa2 in January, and the subsequent $400M unsecured note offering saw strong institutional demand, signaling market confidence in OBDC's credit profile.
Active capital return and buyback program
Repurchased $35 million of stock in Q1 (total $183M over the past two quarters). Board authorized a new $300 million repurchase program in February; approximately $265M remains available after Q1 activity.
Portfolio resilience and diversification
Broadly diversified across ~30 industries with average position size of ~40 bps; borrower revenue and EBITDA grew year-over-year in the high single digits, software borrowers showed low double-digit EBITDA growth.
Meaningful repayments and realizations from high-quality assets
Received meaningful repayments including Intelerad (full repayment after $2.3B sale to GE Healthcare) which reduced software exposure from ~19% to ~16% of the portfolio.
Specialty finance and JV performance
Increased allocation to life sciences specialty finance vehicle (LSI) supporting a $1B financing; LSI has generated returns of >14% to OBDC since inception, highlighting attractive JV/specialty finance economics.
Operational metrics supportive of credit health
Interest coverage improved to ~2.0x (up from trough ~1.6x); average loan marked at ~95.4 and current spread in book ~560 bps, underscoring expected recovery towards par on performing loans.
Long-term track record
On its ten-year anniversary, the fund delivered a 9.6% annualized total return since inception, reinforcing a demonstrated long-term performance history through multiple cycles.